1. Home
  2. KULR vs TLSA Comparison

KULR vs TLSA Comparison

Compare KULR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KULR Technology Group Inc.

KULR

KULR Technology Group Inc.

HOLD

Current Price

$3.83

Market Cap

176.2M

Sector

Technology

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.11

Market Cap

155.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KULR
TLSA
Founded
2013
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
176.2M
155.3M
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
KULR
TLSA
Price
$3.83
$1.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.1M
264.3K
Earning Date
05-15-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,274,028.00
N/A
Revenue This Year
$123.93
N/A
Revenue Next Year
$63.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.08
52 Week High
$7.49
$2.60

Technical Indicators

Market Signals
Indicator
KULR
TLSA
Relative Strength Index (RSI) 49.97 32.88
Support Level $3.03 N/A
Resistance Level $4.47 $1.61
Average True Range (ATR) 0.51 0.12
MACD -0.15 -0.04
Stochastic Oscillator 18.25 9.26

Price Performance

Historical Comparison
KULR
TLSA

About KULR KULR Technology Group Inc.

KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices. The Company operated two segments -EMP and Mining of Digital Assets.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: